Infertility, Female Clinical Trial
Official title:
A Phase III, Multicenter, Blinded, Randomized, Controlled, Parallel, Comparative Study for the Evaluation of Safety and Efficacy of rhFSH Injection Compared With Gonal-F® Pen Undergoing Controlled Ovarian Hyper Stimulation IVF-ET
Verified date | April 2018 |
Source | Hangzhou YuYuan Bioscience Technology Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is for evaluating safety and efficacy of Recombinant human follicle-stimulating hormone (Follitrope) injection compared with Gonal-F® Pen undergoing controlled ovarian hyper stimulation in vitro fertilization - embryo transfer (IVF-ET) in China
Status | Completed |
Enrollment | 451 |
Est. completion date | May 2017 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 39 Years |
Eligibility |
Inclusion Criteria: 1. Infertile adult women between 20 and 39 years at screening. 2. Infertile adult women with regular menstrual cycles of 25 to 35 days at screening. 3. Normal basal serum FSH, LH, E2, and P levels at the early follicular phase at screening. 4. If the cause of infertility is due to following reasons: - Tubal factor - Unknown reason - Male infertility - Combined factors 5. Willing to give voluntary written informed consent. Exclusion Criteria: 1. Patients with a clinically significant systemic disease, endocrine or metabolic abnormalities. 2. Body Mass Index > 30 (BMI; kg/m2) at screening. 3. Patients with a uterine (fibroids (diameter greater than or equal to 2CM endometrium), endometrial polyps, intrauterine adhesions, uterine malformations), ovaries (polycystic ovary, ovarian cysts) or adnexa (hydrosalpinx) abnormalities at screening. 4. patients with uterine, ovarian surgery treatment 5. Patients who experienced of severe ovarian hyperstimulation symptoms (OHSS) in previous IVF cycles. 6. Patients who have shown poor response with gonadotropin hormone therapy. *At least two of the following three features must be present: ? A previous POR(=3 retrieved oocyte with a conventional stimulation protocol) ? An abnormal ovarian reserve test (i.e. AFC < 5 follicles) at screening. 7. Abnormal metrorrhagia due to unknown reason at screening. 8. At least one of husband and wife to accept donor sperm or donor eggs or PGD subject 9. Subjects who are positive for HIV or syphilis at screening. 10. Significant known psychiatric disorder or who unable to understand the objectives and methods, etc. of this clinical trial and unable to comply with the study procedures at screening. 11. Presence of elicit alcohol, smoke or drug abuse habit at screening. 12. History of hypersensitivity to rhFSH or other pharmaceutical excipients of this drug. 13. Participation in any other clinical trial after registering for this study or have participated in another clinical study within 3 month before randomization in this study. 14. History of tumors of the ovary, breast, uterus, hypothalamus or pituary gland. 15. More than 3 times previously consecutive unsuccessful in vitro fertilization cycles at screening. 16. Subjects with no clomiphene citrate or gonadotropin treatment within 1 month before randomization. 17. Positive serum pregnancy test at screening. 18. 14 ± 2 days after the demotion, results of subjects who does not belong to the standard (antral follicle size =10mm) |
Country | Name | City | State |
---|---|---|---|
China | Hangzhou Yuyuan Bioscience Technology Co.,Ltd | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Hangzhou YuYuan Bioscience Technology Co., Ltd. | LG Chem |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The total number of oocytes retrieved | The total number of oocytes retrieved | 15 days after using FSH | |
Secondary | Total dose and duration of FSH administration | Total dose and duration of FSH administration | Throughout the study completion (e.g., 10 days) | |
Secondary | No. of follicles with diameter equal or more than 14 mm on hGH injection day | No. of follicles with diameter equal or more than 14 mm on hGH injection day | The day of hGH injection | |
Secondary | No. of embryo transferred | No. of embryo transferred | 3 days after the ovum pick-up | |
Secondary | Clinical pregnancy rate | Clinical pregnancy rate by g-sac | 5 weeks after the embryo transfer | |
Secondary | On-going pregnancy rate | On-going pregnancy rate by fetal heart-beat | 10 weeks after the embryo transfer |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05969574 -
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
|
||
Recruiting |
NCT05358483 -
PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Completed |
NCT03177538 -
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
|
Phase 4 | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Completed |
NCT04052464 -
The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
|
||
Withdrawn |
NCT04753736 -
Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC
|
N/A | |
Completed |
NCT03349905 -
Deferred Versus Fresh Embryo Transfers
|
N/A | |
Completed |
NCT05076981 -
Progesterone Levels During Ovulation and Luteal Phase
|
||
Completed |
NCT04096027 -
Cabergoline Before or After Oocyte Collection for Follicular Resolution
|
Phase 4 | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Terminated |
NCT01933633 -
Improved Fertility After Exercise in Overweight/Obese Women
|
N/A | |
Terminated |
NCT01202643 -
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
|
Phase 1/Phase 2 | |
Completed |
NCT01202656 -
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
|
Phase 1/Phase 2 | |
Completed |
NCT01408615 -
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
|
||
Enrolling by invitation |
NCT05698550 -
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
|
Phase 3 | |
Not yet recruiting |
NCT03910582 -
Personalized FET in RIF Patients With Displaced Dating
|
N/A | |
Completed |
NCT05440019 -
Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
|
||
Completed |
NCT05130125 -
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
|